Literature DB >> 10907090

Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin.

S K Tahir1, P Kovar, S H Rosenberg, S C Ng.   

Abstract

We have developed a rapid [3H]colchicine competition-binding scintillation proximity assay (SPA) to evaluate antimitotic compounds that bind to the colchicine-binding site on tubulin. The premise of our assay is that compounds will compete with radiolabeled colchicine for the tubulin-binding domain. Biotin-labeled tubulin is incubated first with unlabeled compound and radiolabeled ligand. Streptavidin-labeled SPA beads are added, and the radiolabel associated with tubulin is directly counted with no separation steps. Under our experimental conditions, the dissociation constant of binding (Kd) for colchicine to tubulin was determined to be 1.4 microM, which was consistent with previously reported values. Assay validation was performed by competitively inhibiting [3H]colchicine binding to tubulin with known microtubule inhibitors and comparing their inhibition constants (Ki). Our SPA bead method is a powerful tool since it overcomes the disadvantage of traditional filtration techniques, as there are no separation steps. It is extremely easy to set up, multiple samples can be assayed and supply and labor costs are reduced because of the minimal volume and test reagents used.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10907090     DOI: 10.2144/00291rr02

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  13 in total

1.  Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.

Authors:  Anne-Sophie Belzacq-Casagrande; Florence Bachelot; Catherine De Oliveira; Séverine Coutadeur; Florence Maurier-Mahé; Emeline Throo; Cédric Chauvignac; Laure Pognante; Angélique Petibon; Thierry Taverne; Eric Beausoleil; Bertrand Leblond; Matthew P Pando; Laurent Désiré
Journal:  Invest New Drugs       Date:  2012-08-10       Impact factor: 3.850

2.  Screening Anti-Cancer Drugs against Tubulin using Catch-and-Release Electrospray Ionization Mass Spectrometry.

Authors:  Reza Rezaei Darestani; Philip Winter; Elena N Kitova; Jack A Tuszynski; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2016-03-04       Impact factor: 3.109

3.  Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.

Authors:  Jianjun Chen; Zhao Wang; Chien-Ming Li; Yan Lu; Pavan K Vaddady; Bernd Meibohm; James T Dalton; Duane D Miller; Wei Li
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

4.  6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.

Authors:  Shengnan Du; Jeffrey G Sarver; Christopher J Trabbic; Paul W Erhardt; Allen Schroering; William A Maltese
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-13       Impact factor: 3.333

5.  WTC-01, a novel synthetic oxime-flavone compound, destabilizes microtubules in human nasopharyngeal carcinoma cells in vitro and in vivo.

Authors:  Chang-Ying Chiang; Tai-Chi Wang; Choa-Hsun Lee; Chien-Shu Chen; Shih-Hao Wang; Yu-Chin Lin; Shin-Hun Juang
Journal:  Br J Pharmacol       Date:  2015-08-14       Impact factor: 8.739

6.  Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.

Authors:  Maria Carolina Tuma; Asra Malikzay; Xiaohu Ouyang; David Surguladze; James Fleming; Stan Mitelman; Margarita Camara; Bridget Finnerty; Jacqueline Doody; Eugene L P Chekler; Paul Kussie; James R Tonra
Journal:  Transl Oncol       Date:  2010-10-01       Impact factor: 4.243

7.  Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.

Authors:  Liliya V Frolova; Igor V Magedov; Anntherese E Romero; Menuka Karki; Isaiah Otero; Kathryn Hayden; Nikolai M Evdokimov; Laetitia Moreno Y Banuls; Shiva K Rastogi; W Ross Smith; Shi-Long Lu; Robert Kiss; Charles B Shuster; Ernest Hamel; Tania Betancourt; Snezna Rogelj; Alexander Kornienko
Journal:  J Med Chem       Date:  2013-08-23       Impact factor: 7.446

8.  Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.

Authors:  Zhao Wang; Jianjun Chen; Jin Wang; Sunjoo Ahn; Chien-Ming Li; Yan Lu; Vivian S Loveless; James T Dalton; Duane D Miller; Wei Li
Journal:  Pharm Res       Date:  2012-03-13       Impact factor: 4.200

9.  Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.

Authors:  Chih-Yuan Tseng; Jonathan Y Mane; Philip Winter; Lorelei Johnson; Torin Huzil; Elzbieta Izbicka; Richard F Luduena; Jack A Tuszynski
Journal:  Mol Cancer       Date:  2010-05-30       Impact factor: 27.401

10.  Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.

Authors:  Anahid Ehteda; Peter Galettis; Krishna Pillai; David L Morris
Journal:  BMC Cancer       Date:  2013-02-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.